C3 glomerulopathy: consensus report

Kidney International - Tập 84 Số 6 - Trang 1079-1089 - 2013
Matthew C. Pickering1, Vivette D. D’Agati2, Carla Nester3,4, Richard J. Smith3,4, Mark Haas5, Gerald B. Appel6, Charles E. Alpers7, Ingeborg M. Bajema8, Camille L. Bedrosian9, Michael Braun10, Mittie K. Doyle9, Fádi Fakhouri11, Fernando C. Fervenza12, Agnes B. Fogo13, Véronique Frémeaux‐Bacchi14, Daniel P. Gale15, Elena Goicoechea de Jorge1, Gene Griffin9, Claire L. Harris16, V. Michael Holers17, Sally Johnson18, Peter Lavin19, Nicholas R. Medjeral-Thomas1, B. Paul Morgan16, Cynthia C. Nast5, Laure-Hélène Noël20, D K Peters21, Santiago Rodrı́guez de Córdoba22, Aude Servais23, Sanjeev Sethi24, Wen-Chao Song25, Paul P. Tamburini9, Joshua M. Thurman17, Michael Zavros26, H. Terence Cook1
1Centre for Complement and Inflammation Research, Imperial College London London, UK
2Division of Renal Pathology, Department of Pathology, Columbia University Medical Center and the New York Presbyterian Hospital, New York, New York, USA
3Division of Nephrology, Departments of Internal Medicine and Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
4Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
5Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
6Division of Nephrology, Department of Medicine, Columbia University Medical Center and the New York Presbyterian Hospital, New York, New York, USA
7Department of Pathology, University of Washington, Seattle, Washington USA
8Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
9Alexion Pharmaceuticals, Cheshire, Connecticut, USA
10Division of Pediatric Nephrology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA
11Nephrology Department, Institut de Transplantation Urologie et Nephrologie, CHU de Nantes, Nantes, France
12Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
13Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
14Service d'Immunologie Biologique, Hôpital George Pompidou, AP-HP, Paris, France
15Division of Medicine, Centre for Nephrology, University College London, London, UK
16Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
17Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
18Department of Paediatric Nephrology, Great North Children's Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
19Trinity Health Kidney Centre, Tallaght Hospital, Trinity College, Dublin, Ireland
20INSERM, Service de Néphrologie et de transplantation, Service d'Anatomie Pathologique, Université René Descartes, Hôpital Necker, AP-HP, Paris, France
21Cambridge, UK
22Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas and Centro de Investigación Biomédica en Enfermedades Raras, Ramiro de Maeztu, Madrid, Spain
23Service de Néphrologie et de transplantation, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
24Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
25Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
26Department of Nephrology, Nicosia General Hospital, University of Cyprus, Nicosia, Cyprus

Tóm tắt

Từ khóa


Tài liệu tham khảo

Fakhouri, 2010, C3 glomerulopathy: a new classification, Nat Rev Nephrol, 6, 494, 10.1038/nrneph.2010.85

Martinez-Barricarte, 2010, Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation, J Clin Invest, 120, 3702, 10.1172/JCI43343

Gale, 2010, Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis, Lancet, 376, 794, 10.1016/S0140-6736(10)60670-8

Malik, 2012, A hybrid CFHR3-1 gene causes familial C3 glomerulopathy, J Am Soc Nephrol, 23, 1155, 10.1681/ASN.2012020166

Walker, 2007, Dense deposit disease is not a membranoproliferative glomerulonephritis, Mod Pathol, 20, 605, 10.1038/modpathol.3800773

Servais, 2012, Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, 82, 454, 10.1038/ki.2012.63

Herlitz, 2012, Pathology after eculizumab in dense deposit disease and C3 GN, J Am Soc Nephrol, 23, 1229, 10.1681/ASN.2011121186

Hou, 2013, Toward a working definition of C3 Glomerulopathy by immunofluorescence

Sethi, 2012, Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement, Kidney Int, 83, 293, 10.1038/ki.2012.384

Strobel, 2010, Anti-factor B autoantibody in dense deposit disease, Mol Immunol, 47, 1476, 10.1016/j.molimm.2010.02.002

Chen, 2012, A novel hybrid CFHR2/CFHR5 gene develops MPGN II and provides insights into disease mechanism and therapeutic implications, Immunobiology, 217, 1131, 10.1016/j.imbio.2012.08.009

Tortajada, 2013, C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation, J Clin Invest, 123, 2434, 10.1172/JCI68280

Medjeral-Thomas, 2013, A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry

Abrera-Abeleda, 2011, Allelic variants of complement genes associated with dense deposit disease, J Am Soc Nephrol, 22, 1551, 10.1681/ASN.2010080795

Paixao-Cavalcante, 2012, Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation, Kidney Int, 82, 1084, 10.1038/ki.2012.250

Zhang, 2012, Causes of alternative pathway dysregulation in dense deposit disease, Clin J Am Soc Nephrol, 7, 265, 10.2215/CJN.07900811

Jokiranta, 1999, Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H, J Immunol, 163, 4590, 10.4049/jimmunol.163.8.4590

Nozal, 2012, Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease, Clin Kidney J, 5, 133, 10.1093/ckj/sfs002

Sethi, 2010, Dense deposit disease associated with monoclonal gammopathy of undetermined significance, Am J Kidney Dis, 56, 977, 10.1053/j.ajkd.2010.06.021

Sethi, 2010, Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy, Clin J Am Soc Nephrol, 5, 770, 10.2215/CJN.06760909

Athanasiou, 2011, Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees, Clin J Am Soc Nephrol, 6, 1436, 10.2215/CJN.09541010

Nester, 2013, Treatment options for C3 glomerulopathy, Curr Opin Nephrol Hypertens, 22, 231, 10.1097/MNH.0b013e32835da24c

Appel, 2005, Membranoproliferative glomerulonephritis type II (dense deposit disease): an update, J Am Soc Nephrol, 16, 1392, 10.1681/ASN.2005010078

Group KDIGOKGW, 2012, KDIGO Clinical Practice Guideline for Glomerulonphritis, Kidney Int (Suppl), 2, 198

Daina, 2012, Eculizumab in a patient with dense-deposit disease, N Engl J Med, 366, 1161, 10.1056/NEJMc1112273

McCaughan, 2012, Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies, Am J Transplant, 12, 1046, 10.1111/j.1600-6143.2011.03923.x

Bomback, 2012, Eculizumab for dense deposit disease and C3 glomerulonephritis, Clin J Am Soc Nephrol, 7, 748, 10.2215/CJN.12901211

Licht, 2005, Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15, Am J Kidney Dis, 45, 415, 10.1053/j.ajkd.2004.10.018

Banks, 1982, Acute renal failure in dense deposit disease: recovery after plasmapheresis, Br Med J (Clin Res Ed), 284, 1874, 10.1136/bmj.284.6332.1874-b

Krmar, 2011, Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange, Clin Nephrol, 75, 4

Pickering, 2006, Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice, Proc Natl Acad Sci USA, 103, 9649, 10.1073/pnas.0601094103

Vivarelli, 2012, Eculizumab for the treatment of dense-deposit disease, N Engl J Med, 366, 1163, 10.1056/NEJMc1111953

Little, 2006, Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk, Kidney Int, 69, 504, 10.1038/sj.ki.5000084

Cattran, 2009, The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification, Kidney Int, 76, 534, 10.1038/ki.2009.243

Thông tin
Thông tin xuất bản

Kidney International

Tập 84 Số 6

1079-1089

Thông tin tác giả